Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>BAL-30072

BAL-30072

Katalog-Nr.GC35464

BAL-30072, ein Siderophor-Sulfaktam, ist ein monozyklisches Beta-Lactam-Antibiotikum mit AktivitÄt gegen multiresistente gramnegative Bazillen.

Products are for research use only. Not for human use. We do not sell to patients.

BAL-30072 Chemische Struktur

Cas No.: 941285-15-0

Größe Preis Lagerbestand Menge
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BAL-30072, a siderophore sulfactam, is a monocyclic beta-lactam antibiotic, with activity against multiresistant gram-negative bacilli. BAL30072 shows MIC90 values of 4 μg/mL for MDR Acinetobacter spp. and 8 μg/mL for MDR P. aeruginosa, respectively[1][2]. MIC90: 4 μg/mL (MDR Acinetobacter spp.), 8 μg/mL (MDR P. aeruginosa)[1][2].

[1]. Page MG, et al. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302. [2]. Michael Hornsey, et al. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Int J Antimicrob Agents. 2013 Oct;42(4):343-6.

Bewertungen

Review for BAL-30072

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BAL-30072

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.